Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
NOVAVAX INC incurred convertible notes of $25.25 million with J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC at 5.00% maturing due 2027.
- Instrument
- convertible notes
- Principal
- $25.25 million
- Counterparty
- J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC
- Rate
- 5.00%
- Maturity
- due 2027
- Event
- incurrence
Exact text from the filing
On December 23, 2022, Novavax, Inc. (the “Company”) completed the issuance and sale of $25.25 million aggregate principal amount of the Company’s 5.00% Convertible Senior Notes due 2027 (the “Additional Notes”) to J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, as representatives (the “Representatives”) of the several initial purchasers
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
NOVAVAX INC entered into Purchase Agreement with J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC valued at $25.25 million (effective 2022-12-15).
- Action
- entry
- Agreement
- notes offering
- Counterparty
- J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC
- Value
- $25.25 million
- Effective
- 2022-12-15
Exact text from the filing
On December 23, 2022, Novavax, Inc. (the “Company”) completed the issuance and sale of $25.25 million aggregate principal amount of the Company’s 5.00% Convertible Senior Notes due 2027 (the “Additional Notes”) to J.P. Morgan Securities LLC, Jefferies LLC and Cowen and Company, LLC, as representatives (the “Representatives”) of the several initial purchasers (the “Initial Purchasers”), pursuant to their election to purchase Additional Notes, which was exercised in full, pursuant to the purchase agreement, dated as of December 15, 2022, by and among the Company and the Initial Purchasers (the “Purchase Agreement”).
View on SEC.gov